SAFETY, TOLERABILITY AND PHARMACOKINETICS OF NX-13 IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1 STUDY IN NORMAL HEALTHY VOLUNTEERS

Andrew Leber  ¹     Raquel Hontecillas  ¹     Nuria Tubau-Juni  ¹     Jyoti Chauhan  ¹     Jean-Frédéric Colombel  ²     Simon Lichtiger  ²     Josep Bassaganya-Riera  ^2    
1 Landos Biopharma, Inc., Blacksburg, United States
² Icahn School of Medicine at Mount Sinai, New York, United States

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)